Lipid disulfide prodrugs and uses related thereto
US-10688112-B2 · Jun 23, 2020 · US
US11090316B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11090316-B2 |
| Application number | US-202016899913-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 12, 2020 |
| Priority date | Jul 13, 2017 |
| Publication date | Aug 17, 2021 |
| Grant date | Aug 17, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are disclosed herein.
Opening claim text (preview).
The invention claimed is: 1. A method of treating a viral infection selected from the group consisting of human immunodeficiency virus (HIV) infection and hepatitis B virus (HBV) infection, comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a salt thereof, wherein, W is Z is O, S, or Se; Y is O, S, or NH; T is an aryl or alkyl linking group; R 1 is a saturated hydrocarbon chain having 6 or more carbon atoms; R 2 is R 1 SST-, hydrogen, alkyl, aryl, phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, naphthyl, or heterocyclyl, wherein R 2 is optionally substituted with one or more, the same or different, R 10 ; R 10 is deuterium, alkyl, alkenyl, alkynyl, alkanoyl, halogen, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy, carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl) 2 amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl, carbocyclyl, aryl, or heterocyclyl, wherein R 10 is optionally substituted with one or more, the same or different, R 11 ; and R 11 is deuterium, halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methyl sulfinyl, ethylsulfinyl, mesyl, ethyl sulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, benzyl, benzoyl, carbocyclyl, aryl, or heterocyclyl. 2. The method of claim 1 , wherein T is a C 2 to C 6 alkyl. 3. The method of claim 1 , wherein Z and Y are each O. 4. The method of claim 1 , wherein R 1 is a C 6 to C 20 saturated hydrocarbon chain. 5. The method of claim 1 , wherein R 2 is R 1 SST-, hydrogen, alkyl, aryl or phenyl. 6. The method of claim 1 , wherein R 2 is hydrogen, methyl, or alkyl. 7. The method of claim 1 , wherein the compound is selected from the following compounds as free acids or salts thereof: 8. The method of claim 1 wherein the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with the viral infection. 9. The method of claim 1 wherein the compound is administered in combination with another antiviral agent. 10. The method of claim 1 , wherein T is —(CH 2 ) n —, wherein n is 2, 3, 4, 5, or 6. 11. The method of claim 10 , wherein n is 2. 12. The method of claim 10 , wherein n is 4 or 5. 13. The method of claim 1 , wherein T is —C 6 H 4 —, —CH 2 —C 6 H 4 —, —C 6 H 4 —CH 2 —, or —CH 2 —C 6 H 4 —CH 2 —. 14. The method of claim 1 , wherein the viral infection is HIV infection. 15. The method of claim 1 , wherein the viral infection is HBV infection.
Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Antivirals · CPC title
Purines, e.g. adenine · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.